+1803294983432
customer.service@microbix.com
PAST EVENTS
Microbix Commercializes SARS-CoV-2 (COVID) Recombinant Antigen
Microbix announces the commercial usage of its first recombinant antigen product, the nucleocapsid protein of the SARS-CoV-2 virus (COVID-19), in its quality assessment products (“QAPs™”) and its availability at commercial scale for test manufacturers.
Microbix Reports Results for Q4 and Fiscal 2025
Full-Year Revenues of $18.6 million and Net Loss of $2.2 million MISSISSAUGA, CANADA, December 18, 2025 - Microbix Biosystems Inc....
Microbix Schedules Release of Results for Q4 Fiscal 2025
Results Release and Webinar Discussion on Morning of December 18, 2025 MISSISSAUGA, CANADA, December 11, 2025 - Microbix Biosystems...
Microbix Launches New Products to Support H3N2 Flu Testing
Test-Controls & Reference Materials for Labs & Test-Makers MISSISSAUGA, CANADA, December 10, 2025 – Microbix Biosystems...
Microbix Announces Initiation of Normal Course Issuer Bid
For Repurchase of up to 5% of its outstanding shares over 12 months MISSISSAUGA, CANADA, December 4, 2025 – Microbix Biosystems...
